Compared with that of insulin administration alone, administration of SGLT-2 inhibitors, such as dapagliflozin, empagliflozin, and canagliflozin, decreased HbA1c level, body weight, and insulin requirement in patients with T1D (18–23). The gene discussed is SLC5A2; the disease is type 1 diabetes mellitus.